Making It Work In The USA

The success of the ABHI’s Innovation Hub at the Dell Medical School at the University of Texas in Austin is growing and it is case studies such as ours published this month that is helping demonstrate the importance of the Association’s work in building opportunities for British companies.    Read our story here.

Forte Medical: Series A investment growth round is open

This week saw the launch of Forte Medical’s Series A investment round for growth, export and new product development. Seeking £3.5m, the company is engaging with prospective investment partners who can attract investors with an interest in evidenced, disruptive diagnostic medical devices with digital potential.

Institutional, corporate or personal investors who can assist the business long term are seen as the most promising and attractive partners. For more information, contact our CEO Giovanna Forte.

Giovanna Forte on TV

Disruptive TV: Giant Live Health Innovators

Barry Shrier, Founder of annual health innovation event Giant Live, presents the third Disruptor Giant Health Innovators TV interview featuring Giovanna Forte, CEO of Forte Medical, Francis White from AliveCor, Dr Sophie Bostoc​k of Sleepio and Etienne Bourdon from Healthy Health. Watch the half-hour programme here with Disruptive Live

The Sunday Times Maserati 100 Entrepreneurs 2018

“The entrepreneurs celebrated in this year’s Maserati 100 like to get things done’ said Sunday Times’ journalist Andrew Lynch in his introduction to this year’s list of the top 100 entrepreneurs in 2018. And that is pretty true of Forte Medical’s founder and CEO, Giovanna Forte who was featured in the People’s Choice.

Giovanna set up the company to introduce the MedTech invention of her brother, NHS GP Dr Vincent Forte to healthcare providers seeking clinical integrity and cost savings.

Dr Forte questioned the frequency of second and third appointments to cure common UTI, which were taking up valuable surgery time. His investigations concluded that unreliable urine specimens were preventing right-first-time analysis, diagnosis and targeted treatment.

Peezy Midstream delivers 98.5% accuracy, bringing integrity to basic medicine and patient care, delivering efficiency and cost savings across the healthcare pathway.

Our new products will deliver accurate specimen collection for a range of novel cancer urine tests, sports dope testing and more. The Forte Medical Specimen Collection is destined to become eponymous across diagnostic medicine.

Urine infection medication

AMR: A Heavy Price To Pay

News from the USA: “the share of bacterial infections in the United States that were antibiotic resistant more than doubled over 13 years, rising from 5.2% in 2002 to 11% in 2014”

To read more, click here

Med-Tech Innovation Expo – April 2018

Giovanna Forte is one of the guest speakers at this two day and her presentation: “Urine Trouble – How Innovation is Transforming Basic Medicine” – will be given on Thursday, 26th April at 1.30 pm.

For further information about the event conference and exhibition go here

£434 million spent on treating unplanned UTI admissions

It costs so little to put it right: “The NHS spent £434 million in 2013/14 on treating184,000 patients in unplanned admissions associated with a UTI.   UTIs are the second-largest single group of healthcare-associated infections in the UK, accounting for 19.7% of all hospital acquired infections.”

Source:  Unplanned Admissions Consensus Committee – 2016 Updated Guide

Preventing Infections and Reducing AMR

An advocate and active player in healthcare infection prevention, we will participating at the Knowlex Infection Prevention and Control 2018 exhibition being held on Wednesday, 21st February 2018 at The Brewery, London EC1Y 4SD.    It is the event to hear more about  the latest research, science, innovation and discover real-world solutions in the challenge against infection prevention  Further event information can be found here.

Texas MedTech Mission Create Demand for British Goods

Paul Benton, International Director at the ABHI shares our story as to how we entered the US marketplace

Appointed sales and distribution partners, dedicated warehouse facilities and new US customers are just some of the outcomes from the UK MedTech missions to Texas.  Read more

New Forte Medical Advisory Board

Encouraged by the growing national recognition of the value of urine in diagnostic medicine, health leaders are being approached to join a new Forte Medical Advisory Board. Three leading exponents of accurate basic medicine have so far been appointed: Mike Farrar (pic) who will Chair the panel, Dr Katherine Brown and Rachel Cashman

Mike Farrar is a management consultant with 15 years of CEO experience in the NHS, having stepped down as the Chief Executive of the NHS Confederation in September 2013.  Mike has been a member of the PwC Health Industries Oversight Board and has worked on major projects across the country. Mike has also built alongside this a successful business practice working with clients such as Celesio, ROGP, ABPI, NHS Quest, NHS Leadership Academy, Health Foundation, Vanguard Health Solutions, Pfizer, CIPFA and others, as well as starting up a number of small companies aimed at promoting health innovations, and links between health and sport.

He has been Chief Executive of North West England SHA, West Yorkshire, and South Yorkshire Strategic Health Authorities and Tees Valley Health Authority and Head of Primary Care at the Department of Health. Mike remains a prominent thought leader and consultant to the NHS throughout the UK

Dr Katherine Brown is an academic based in the UK and the US with over 100 peer-reviewed publications.  She is affiliated with Cambridge and Imperial Universities and the University of Texas. With over 25 years in medical applications, she has extensive expertise in biochemistry, biophysics, infectious disease and bio/nanotechnology.

Rachel Cashman is Managing Director, The Soircas Consultancy and former Head of Clinical and Scientific Policy and Strategy, NHS England

During her 20+ years in the healthcare and life sciences sectors, Rachel has delivered large-scale change and innovation through inter-sectoral collaboration and the development of networks. At NHS England, she led the establishment of Academic Health Science Networks (AHSNs) and the process to create the first nationally commissioned network of Genomic Medicine Centres, utilising the latest scientific techniques in understanding human DNA in order to better predict, precisely diagnose and personalise treatment of cancers and rare disease.

She has worked with NHS Trusts and CCGs and their local health and care system partners to develop appropriate governance and infrastructure in response to the NHS Five Year Forward View and the emergence of the Sustainability and Transformation Partnerships. As a Board member at University Hospitals Birmingham NHS Foundation Trust and Heart of England NHS Trust, Rachel designed the strategic business case and engagement process for the proposed merger. Rachel has played an integral role in helping the NHS utilise rapid assessment protocols to evaluate potential partnership opportunities such as hospital chains, franchise models, mergers, accountable care organisations and multi-specialty community provider organisations.